4473-25-0

Basic information

• Product Name: 1,2-Benzisothiazol-3(2H)-one, 2-(2-chlorophenyl)-
• CAS NO: 4473-25-0
• Molecular Formula: C13H8ClNOS
• Molecular Weight: 261.732
• Mol File: 4473-25-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,2-Benzisothiazol-3(2H)-one, 2-(2-chlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzisothiazol-3(2H)-one, 2-(2-chlorophenyl)-(4473-25-0)
• EPA Substance Registry System: 1,2-Benzisothiazol-3(2H)-one, 2-(2-chlorophenyl)-(4473-25-0)

Safety Data

• Hazardous Substances Data: 4473-25-0(Hazardous Substances Data)

Usage

Appearance

White to off-white solid

Solubility

Moderately soluble in water and organic solvents

Uses

Biocidal agent
Preservative in industrial and commercial applications
Water treatment
Pulp and paper processing
Wood preservation
Fungicide and bactericide in agricultural and horticultural products
Corrosion inhibitor in metalworking fluids
Antimicrobial agent in consumer products (paints, adhesives, and textiles)

Regulatory status

Regulated in many countries due to potential toxicity and environmental impact

Safety and handling precautions

Strict safety and handling precautions required due to potential toxicity and environmental impact

Upstream product

• 3950-02-5 2-chlorosulfenylbenzoyl chloride 
• 95-51-2 o-chloroaniline 
• 147-93-3 Thiosalicylic acid 
• 19602-82-5 2,2'-dithiodibenzoic acid dichloride 
• 119-80-2 2,2'-dithiobenzoic acid 

Relevant articles and documents

Facile synthesis and in vitro activity of n-substituted 1,2-benzisothiazol-3(2H)-ones against dengue virus NS2BNS3 protease

Several new N-substituted 1,2-benzisothiazol-3(2H)-ones (BITs) were synthesised through a facile synthetic route for testing their anti-dengue protease inhibition. Contrary to the conventional multistep synthesis, we achieved structurally diverse BITs with excellent yields using a two-step, one-pot reaction strategy. All the synthesised compounds were prescreened for drug-like properties using the online Swiss Absorption, Distribution, Metabolism and Elimination (SwissADME) model, indicating their favourable pharmaceutical properties. Thus, the synthesised BITs were tested for inhibitory activity against the recombinant dengue virus serotype-2 (DENV-2) NS2BNS3 protease. Dose–response experiments and computational docking analyses revealed that several BITs bind to the protease in the vicinity of the catalytic triad with IC50 values in the micromolar range. The DENV2 infection assay showed that two BITs, 2-(2-chlorophenyl)benzo[d]isothiazol-3(2H)-one and 2-(2,6-dichlorophenyl)benzo[d]isothiazol-3(2H)-one, could suppress DENV replication and virus infectivity. These results indicate the potential of BITs for developing new anti-dengue therapeutics.

Treatment of rheumatism and arteriosclerosis with n-halogenophenyl-benzisothiazoles

The invention relates to the new use of certain benzisothiazoles corresponding to the following general formula: STR1 wherein R1 represents chlorine, fluorine or bromine, and R2 represents hydrogen, chlorine, fluorine or bromine, in the treatment of phlogistic and/or arteriosclerotic processes.